CHRU Nancy
Vandœuvre-lès-Nancy, France
NCT Number: NCT04429815
Several studies have shown that smokers have a higher risk of developing a severe form of COVID-19 once a person has been infected. This is explained by the damage caused by smoking at the bronchopulmonary level and an overexpression of some coronavirus receptors at the pulmonary level when exposed to tobacco. In contrast, recent data indicate that smokers are proportionally less infected with the COVID-19 virus since all available cohort data from around the world show a very low rate of smokers among COVID-19 infected subjects. The mechanisms at the origin of this protective effect are not known. All of these data lead us to question the real role of nicotine in the protective effect of tobacco observed in the general population against infection by the COVID-19 virus.
The objectives are :
* To show that subjects taking nicotine substitutes as part of a smoking cessation program are less infected with COVID-19 than non-smokers. * To show that active smokers are less infected with COVID-19 than non-smokers. * To compare the percentage of positive serological tests in subjects taking nicotine substitutes to the percentage of positive serological tests in active smokers.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Vandœuvre-lès-Nancy, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Serological test for COVID-19 performed as part of standard of care.
Time frame: 1 day
Percentage of patients with a positive serological test for COVID-19.
Central Hospital, Nancy, France
Other
Acronym: MAGIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06191419
Behavior, Chemically-Induced Disorders
Lexington, Kentucky, United States
View Trial DetailsNCT03083353
Behavior, Chemically-Induced Disorders
Austin, Texas, United States
View Trial DetailsNCT07092501
Behavior, Cigarette
Roanoke, Virginia, United States
View Trial DetailsNCT05490251
Behavior, Fractures, Bone
Los Angeles, California, United States
View Trial Details